AIFF — Firefly Neuroscience Share Price
Last trade - 00:00- $27.25m
- $24.12m
- $1.14m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.23 | ||
| Price to Tang. Book | 11.15 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 17.2 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -104.08% | ||
| Return on Equity | -136.27% | ||
| Operating Margin | -555.62% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 15.03 | 11.02 | 7.98 | 0.11 | 1.14 | n/a | n/a | -39.34% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Firefly Neuroscience, Inc. is an artificial intelligence (AI) company advancing precision neuroscience. The Company's BNA Platform and Evoke System are Class II medical devices, which were cleared by FDA for commercialization. The Company's FDA-510(k) cleared Evoke System, commercially deployed as the Evoke System, is in active use over 85 clinical sites in the United States. The Company has developed Firefly Platform, a vertically integrated hardware, software, and data infrastructure that captures standardized electroencephalographic (EEG) and event-related potential (ERP) assessments at the point of care, analyzes that data through its proprietary analytics engine, and delivers structured, clinician-ready reports back to the provider, all within a single seamless workflow. Its proprietary analytics engine analyzes raw EEG and ERP signals across captured dimensions and compares each patient’s electrophysiological profile to a reference dataset.
Directors
- G. James Benoit CHM (49)
- Stanley Reese PRE (64)
- Timothy Hannon CFO (57)
- Matthew Sands SVF (50)
- Randy Boone OTH
- Heather Tortorelli OTH
- Paul Becker DRC
- James Dipaula DRC
- Donald Tringali DRC (63)
- Jack Johnson IND (64)
- Mark Krial IND (63)
- Charles May IND (83)
- William Pickle IND (71)
- Bonnie Wachtel IND (65)
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- December 14th, 2021
- Public Since
- October 27th, 1993
- No. of Shareholders
- 354
- No. of Employees
- 17
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 15,571,780
- Address
- 1100 Military Road, KENMORE, 14217
- Web
- https://fireflyneuro.com/
- Phone
- +1 3026587581
- Contact
- Stephen Kilmer
- Auditors
- Turner, Stone & Company
Upcoming Events for AIFF
Similar to AIFF
36Kr Holdings
NASDAQ Capital Market
3 E Network Technology
NASDAQ Capital Market
A2Z Cust2mate Solutions
NASDAQ Capital Market
Abits
NASDAQ Capital Market
Acorn Energy
NASDAQ Capital Market
FAQ
As of Today at 20:37 UTC, shares in Firefly Neuroscience are trading at $1.75. This share price information is delayed by 15 minutes.
Shares in Firefly Neuroscience last closed at $1.75 and the price had moved by -47.92% over the past 365 days. In terms of relative price strength the Firefly Neuroscience share price has underperformed the S&P500 Index by -59.56% over the past year.
There is no consensus recommendation for this security.
Find out moreFirefly Neuroscience does not currently pay a dividend.
Firefly Neuroscience does not currently pay a dividend.
Firefly Neuroscience does not currently pay a dividend.
To buy shares in Firefly Neuroscience you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.75, shares in Firefly Neuroscience had a market capitalisation of $27.25m.
Here are the trading details for Firefly Neuroscience:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AIFF
Based on an overall assessment of its quality, value and momentum Firefly Neuroscience is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Firefly Neuroscience. Over the past six months, its share price has underperformed the S&P500 Index by -0.63%.
As of the last closing price of $1.75, shares in Firefly Neuroscience were trading -5.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Firefly Neuroscience PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Firefly Neuroscience's management team is headed by:
- G. James Benoit - CHM
- Stanley Reese - PRE
- Timothy Hannon - CFO
- Matthew Sands - SVF
- Randy Boone - OTH
- Heather Tortorelli - OTH
- Paul Becker - DRC
- James Dipaula - DRC
- Donald Tringali - DRC
- Jack Johnson - IND
- Mark Krial - IND
- Charles May - IND
- William Pickle - IND
- Bonnie Wachtel - IND